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Designed Spiroketal Protein Modulation
Marcel Scheepstra, Sebastian A. Andrei, M. Yagiz Unver, Anna K. H. Hirsch, Seppe Leysen,
Christian Ottmann, Luc Brunsveld,* and Lech-Gustav Milroy*
Abstract: Spiroketals are structural motifs found in many
biologically active natural products, which has stimulated
considerable efforts toward their synthesis and interest in their
use as drug lead compounds. Despite this, the use of
spiroketals, and especially bisbenzanulated spiroketals, in
a structure-based drug discovery setting has not been convinc-
ingly demonstrated. Herein, we report the rational design of
a bisbenzannulated spiroketal that potently binds to the
retinoid X receptor (RXR) thereby inducing partial co-
activator recruitment. We solved the crystal structure of the
spiroketal–hRXRa–TIF2 ternary complex, and identified
a canonical allosteric mechanism as a possible explanation
for the partial agonist behavior of our spiroketal. Our co-
crystal structure, the first of a designed spiroketal–protein
complex, suggests that spiroketals can be designed to selectively
target other nuclear receptor subtypes.
Spiroketals are archetypal spirocyclic compounds,[1] found
abundantly in the CAS registry (Supporting Information), of
which many are bioactive natural products.[2,3] Besides being
attractive targets for total synthesis,[4–6] spiroketal-derived
natural products have contributed to a renaissance of thinking
towards intelligent library design, grounded in principles of
diversity-oriented synthesis (DOS)[7] and biology-oriented
synthesis (BIOS).[8,9] Spiroketals are arguably well-adapted to
both philosophical approaches in being biologically rele-
vant[2,3] while fulfilling the three criteria for molecular
diversity set out by Schreiber and co-workers—appendage,
stereochemistry, skeletal diversity[7]—owing in particular to
the conformational and configurational flexibility of these
scaffold structures. A BIOS study on spiroketals performed
by Waldmann and co-workers[10–12] clearly placed these
structures within a hierarchical classification of bioactive
scaffold structures, navigable with the help of cheminformat-
ics tools such as Scaffold Hunter,[15] and inspired the design of
other spiroketal libraries for phenotypic screening.[13,14]
Recently, 3D-pharmacophore modelling was used to
design spiroketal-derived sugars, which showed inhibitory
activity towards SGLT2.[19] To the best of our knowledge, the
co-crystal structure of bistramide A bound to actin,[20] and the
bis-spiroketals pinnatoxins A and G[21] are to date the only
examples of spiroketals bound to protein targets. Benzannu-
lated spiroketals are a relevant subtype of spiroketals,[3] which
includes the antibiotic rubromycin family (Figure 1A).[22]
Figure 1. Design of a spiroketal as RXR ligand. a) Molecular structures
of g-rubromycin, [6,6]-bisbenzannulated spiroketal 1 and RXR full
agonists, BMS 649[16] and LG100268. b) Top-ranked pose of R-1 gener-
ated by docking into the space occupied by BMS 649 in the hRXRa-
BMS 649 co-crystal structure (PDB code: 1MVC)[16] using the FlexX
docking module in the LeadIT suite[17] followed by HYDE scoring in
SEESAR.[18] R-1 skeleton: C=pink, O= red; protein backbone:
C=green, N=blue, O= red, S= yellow; dashed lines=H-bonding
interactions below 3.3 b.
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Recent reports have revealed that these molecules function as
telomerase inhibitors, with the [6,5]-spiroketal ring system in
this case playing an essential role in the rubromycinQs
pharmacophore.[22] Despite the abundance of spiroketals
and their highlighted potential as medicinal chemistry scaf-
folds, the structure-based design and structural validation of
spiroketals as medicinal chemistry scaffolds has not been
clearly demonstrated.
A reported crystal structure of a [6,6]-bisbenzannulated
spiroketal[23] inspired us to consider these structures as
nuclear receptor (NR) ligands, which we speculated would
possess the correct size, shape, and hydrophobicity to target
the L-shaped ligand binding pocket (LBP) of the retinoid X
receptor (RXR),[24] a member of the superfamily of gene
transcription factors. RXR plays a central role in hormone-
driven cell-signaling events through its ability to heterodi-
merize with other type II nuclear receptors.[25] RXR is a drug
target for the treatment of cutaneous T-cell lymphoma and is
under investigation as a potential treatment for AlzheimerQs
Disease.[26] Despite the fact that RXR ligands have been
thoroughly investigated,[27] only a very few RXR partial
agonists with limited structural diversity have been charac-
terized, and rules guiding the design of heterodimer-specific
RXR ligands are essentially non-existent. In part as a response
to these challenges, and in continuation of our groupQs recent
efforts to identify selective RXR[28] and other NR modula-
tors,[29] we report the first designed spiroketal protein
modulator, as exemplified by RXR modulation.
To assess the potential of bisbenzannulated spiroketals
to target RXR, we adopt a classical scaffold-hopping
approach[30] commencing with the co-crystal structure of
commercial nanomolar-potent RXR full agonist BMS 649
(otherwise known as SR11237)[31] bound to hRXRa (PDB
code: 1MVC).[16] We then replaced the rigid acetal linker
present in BMS 649 with a [6-6]-bisbenzannulated spiroketal
linker while retaining the key tetramethyl-tetrahydro-
naphthyl- and carboxylic acid groups,[32] to generate 1. We
then modelled and docked both enantiomers of 1 into the
space occupied by BMS 649 in the LBD of the hRXRa-BMS
649 co-crystal structure[16] using the FlexX docking module in
the LeadIT suite followed by evaluation using the scoring
function HYDE in SEESAR (Figure 1). While all attempts at
docking the S-enantiomer in this PDB structure failed to
generate poses, we succeeded in docking the R-enantiomer,
with the best pose shown in Figure 1B. Although our docking
studies did not take into account the thermodynamic prefer-
ences of the spiroketal ring system, interestingly, R-1 adopts
a diaxial ring conformation, which would be favored owing to
bis-anomeric stabilization. In this ring conformation favor-
able polar interactions are maintained between the carboxylic
acid of R-1, Arg316, and the backbone of Ala327.
To enable an expedient testing of our binding hypothesis,
we elected for a racemic synthesis of (:)-1, with a view to
separating the enantiomeric spiroketals by chiral HPLC at
a later stage. In reported syntheses of [6,5]-[33, 34] and [6,6]-
bisbenzannulated spiroketals,[3] the spiroketal core is fre-
quently formed under thermodynamically driven conditions
through a dehydrative ring cyclisation. Our synthesis of (:)-
1was based on work by Brimble and co-workers on analogous
[6,6]-bisbenzannulated spiroketals[23] and is described in
Scheme 1. We reacted aldehyde 3 with the lithium acetylide
of 2 to obtain alkynol 4 in a reasonable 58% yield. After
subsequent catalytic hydrogenation of 4, we performed
a Dess–Martin oxidation on the resulting secondary alcohol
5 to generate the spirocyclization precursor, 6, which we
treated with trimethylsilyl bromide to effect a one-pot
deprotection/cyclization, which produced the [6,6]-bisben-
zannulated spiroketal 7 in a yield of 64%. The synthesis of
(:)-1 concluded with a straightforward base-mediated
hydrolysis of the methyl ester group. The resonance peak at
dc 97.0 ppm in the 13C-NMR spectra of 7 and (:)-1 is
diagnostic for the spirocarbon, while the 1H resonances
corresponding to the two sets of diastereotopic protons H3,
H3’, H4 and H4’ suggest that the spiroketal adopts a diaxial ring
conformation (Supporting Information) similar to analogous
structures.[23]
We profiled the RXRa-activity of (:)-1 alongside full
agonist LG100268 (Figure 1A)[36] in a fluorescence-based
cofactor recruitment assay (Figure 2, left and Table 1). As
expected,[28] LG100268 induced potent recruitment of the
D22 peptide[37] with an EC50= 0.10: 0.01 mm. Intriguingly,
(:)-1 was also active, with an EC50= 0.73: 0.06 mm, and
additionally exhibited a partial agonist behavior, as judged by
the levelling off of polarization at 53% of the maximum
response induced by LG100268. We tested (:)-1 against two
other LXXLL-derived peptides (Table 1), ribosome display
peptide Pro22[35] and the naturally occurring peptide TIF2,[38]
and observed similar EC50 values but different % efficacies.
One of the separated enantiomers, 1-ent1, was found to
approach the potency of LG100268 in the same FP assay
(Figure 2, left and Table 1). Furthermore, 1-ent1 displayed
seven-fold higher potency and two-fold higher % efficacy
than the other enantiomer, 1-ent2. The isolated enantiomers
did not evidently epimerize under the acidic separation
Scheme 1. Reagents and conditions: a) n-BuLi, THF, @78 8C to RT;
b) 10% Pd/C, KHCO3, EtOAc, RT; c) Dess–Martin periodinane,
CH2Cl2, RT; d) TMSBr, CH2Cl2, @30 8C to RT; e) NaOH, dioxane/
MeOH, 40 8C. Characteristic 1H and 13C resonance peaks are summar-
ized for 7 and (:)-1.[23]
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conditions (Supporting Information) nor was any significant
change in EC50 value observed for either 1-ent1 or 1-ent2 in
the same FP assay over a 24 h period (Supporting Informa-
tion) as evidence of the stability of these compounds under
the aqueous assay conditions. Our findings are consistent with
those from studies on similar benzannulated spiroketals[39]
and the fact that analogous natural products are isolated as
single enantiomers.[40]
To evaluate 1 under more biologically relevant conditions,
we compared (:)-1 and LG100268 in a mammalian two-
hybrid (M2H) luciferase assay (Figure 2, right). As
expected,[28] LG100268 produced a full and potent concen-
tration-dependent response (Figure 2, right). (:)-1 was also
active under the assay conditions, though less potent than
LG100268, and the partial response less emphatic than that
observed in the FP assay. The difference in % efficacy
observed for (:)-1 in both the in vitro FP and cellular M2H
assays might be explained by differences in protein concen-
tration between the two assay formats. Nevertheless, we could
conclude that (:)-1 is cell permeable and active toward gene
transcription similarly to an established RXR full agonist.
To provide a structural explanation for the observed RXR
activity, we co-crystallized (:)-1 with the hRXRa LBD-TIF2
peptide complex and solved the structure to a resolution of
2.17c (Figure 3). Globally, the protein adopts a canonical,[41]
agonistic, folded state with the helix co-activator bound to the
AF2 (Figure 3A). Closer inspection of the RXR LBP
revealed clear electron density indicative of a single spiroke-
tal molecule. On closer inspection, theR-enantiomer, with the
spiroketal ring system in a bis-anomeric diaxial conformation,
fitted best in the electron density (Figure 3C and Supporting
Information). The carboxylate group of R-1 engages in
a canonical polar interaction with the side chain of Arg316
and hydrogen bonds with the protein backbone at residue
Ala327 (Figure 3B). Interestingly, despite our inability to
generate docking poses for S-1 in our initial model (Figure 1),
we were able to dock S-1 into the space created by R-1 in the
LBP of our hRXRa-R-1 co-crystal structure (Supporting
Information). The contrast between this success and the
docking studies highlights an imperfection of molecular
docking on account of the dynamic behavior of protein
folding and the need for caution when interpreting docking
results. Nevertheless, in contrast to R-1, our best docking pose
Figure 3. X-ray co-crystallography data. a) Ribbon representation of the
X-ray co-crystal structure of R-1 (orange stick) bound to the ligand-
binding pocket (LBP) of hRXRa (green ribbon) with the TIF2 co-
activator-derived peptide (blue ribbon) PDB code: 5LYQ. b) Enlarged
view of the hRXRa LBP with the amino acid side chains labelled and
represented as sticks. c) Superimposition of R-1 and final 2Fo@Fc
electron density map (contoured at 1s). d) Superimposition of the LBP
region of hRXRa bound to R-1 (protein in green, ligand in orange,
PDB code: 5LYQ) and a documented full agonist (protein in red,
ligand in cyan, PDB code: 40C7).[28] The TIF2 peptide corresponding to
PDB code 40C7 is shown in cyan. Participating helices/residues/atoms
are labelled. Orange arrows indicate movement in protein conforma-
tion from an agonistic (red) to the folded state induced by R-1 (green).
The loop region connecting helix 11 (H11) to H12-443GDTPID448 is
hidden for clarity.
Figure 2. Biochemical and cellular evaluation of (:)-1. Left: Fluores-
cence polarization assay data showing that full agonist LG100268
induces binding of the fluorescently labelled D22 peptide in a concen-
tration-dependent manner, while (:)-1, 1-ent1, and 1-ent2 (separable
by chiral HPLC) each exhibit a partial agonist behavior. Right: Cellular
activities of LG100268 and (:)-1 measured in a mammalian two-
hybrid luciferase assay. Error bars denote s.d. (n=3).
Table 1: Summary of FP and cellular M2H data.
Compound Fluorescence Polarization
Peptide[a] EC50 (:) [mm] %eff
LG100268 D22[b] 0.10 (0.01) 100
TIF2[c] 0.48 (0.02) 100
Pro22[c] 0.25 (0.01) 100
(:)-1 D22[b] 0.73 (0.06) 53
TIF2[c] 0.47 (0.06) 28
Pro22[c] 0.43 (0.01) 59
1-ent1 D22[b] 0.17 (0.02) 54
1-ent2 D22[b] 1.20 (0.33) 26
[a] Peptide sequences: D22=FAM-LPYEGSLLLKLLRAPVEEV;
TIF2=FITC-Ahx-KHKILHRLLQDSS-NH2; Pro22=FITC-Ahx-
LTARHPLLMRLLLSPS-NH2.[35] [b] See Figure 2. [c] Refer to the Support-
ing Information for the binding curves.
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for S-1 placed the spiroketal ring system in a thermodynami-
cally less-favorable axial–equatorial conformation. There-
fore, we logically assign 1-ent1 to be R-1 and 1-ent2 to be S-1,
and tentatively speculate that the weaker activity observed
for S-1 in the FP assay may result from a protein-induced fit of
the spiroketal to the RXR LBP via the postulated axial–
equatorial conformation.
In search of a plausible structural basis for the RXR
activity of our spiroketals, we superimposed the co-crystal
structure of hRXRa–R-1–TIF2 with a previously published
crystal structure of hRXRa–TIF2 bound to a potent full
agonist (Figure 3D).[28] Compared to the full agonist, the
binding of R-1 results in a circa 1c displacement of the side
chain of Leu436 in H11 and the C-terminal region of H11,
which would perturb H12 binding, and potentially destabilize
coactivator peptide binding as a possible cause of the partial
agonist effect observed in the FP data. A similar sequence of
side-chain displacements has been cited by Nahoum et al. to
explain the partial agonist behavior of structurally different
biaryl RXR ligands reported,[42] thus hinting at a general
mechanism for RXR partial agonism.
In conclusion, we report the structure-based design,
synthesis, and biochemical as well as structural evaluation of
a bisbenzannulated spiroketal as a potent modulator of the
RXRa gene transcription factor. Our work includes a rare co-
crystal structure of a spiroketal,[20, 21]which is to the best of our
knowledge the first of a benzannulated spiroketal bound to
a protein target. We believe that the apparent RXR partial
agonist behavior of our spiroketal contributes to establishing
partial agonism[43] as a concept for RXR.[42,44] Furthermore,
the high structural homology of the LBP across the NR
superfamily,[41] combined with the structural versatility of
spiroketals, suggests that spiroketals can be designed to
selectively target other NR subtypes as forerunner to the
designed modulation of other protein targets.
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